{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:45:31Z","timestamp":1787024731593,"version":"build-2736575974"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>A series of novel, substituted tetracyclic benzothiazepines were designed and prepared in an effort to optimize potency of this chemical class against drug-resistant strains of the malaria parasite.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Tetracyclic benzothiazepines bearing structural modification at seven distinct positions within the structure were synthesized, in Knoevenagel condensation reactions followed by sequential intermolecular thio-Michael and then intramolecular imine formation reactions.  Following purification and chemical characterization, the novel compounds were tested for in vitro efficacy against blood-stage P. falciparum and liver-stage P. berghei, and also for in vivo efficacy against P. berghei.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Benzothiazepines bearing structural modification at the sulfur atom and at the three carbocycles within the molecule were successfully synthesized.  The majority of analogs inhibited blood-stage P. falciparum with submicromolar IC50 values.  The potency of an 8-methoxy-substituted analog 12 exceeded that of chloroquine in all three P. falciparum strains tested.  The parent benzothiazepine 1 possessed liver-stage activity, inhibiting P. berghei sporozoites infecting HepG2 cells with an IC50 of 106.4 nM and an IC90 of 408.9 nM, but failed to enhance the longevity of P. berghei infected mice compared to the controls.  Compounds displayed modest toxicity toward HepG2 cells, and were tolerated by mice at the highest dose tested, 640 mg\/kg\/dose once daily for three days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The tetracyclic benzothiazepine described, which inhibits P. berghei infected hepatic cells with an IC50 of 106.4 nM, would appear to warrant further investigation.  Optimization of ADME properties may be required, since the most active analogs are probably excessively lipophilic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1573406418666220820112324","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T06:50:04Z","timestamp":1660978204000},"page":"478-484","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synthesis and In vitro Efficacy of Tetracyclic Benzothiazepines Against\nBlood-Stage Plasmodium falciparum and Liver-Stage P. berghei"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-8657","authenticated-orcid":true,"given":"Clare E.","family":"Gutteridge","sequence":"first","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sadowski","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alan","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia D.","family":"Gaidry","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Baxter","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leighton G.","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Chemistry, United States Naval Academy, Annapolis, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"O'Neil","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gerena","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadas","family":"Sathunuru","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montip","family":"Gettayacamin","sequence":"additional","affiliation":[{"name":"Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","volume":"2021","year":"2021","unstructured":"World Health Organization, World Malaria Report Available from: 2021, (Accessed on Mar 01, 2022).2021,2021"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1042\/bse0510137","volume":"51","author":"S&#xE1; J.M.","year":"2011","unstructured":"S&#xE1; J.M.; Chong J.L.; Wellems T.E.; Malaria drug resistance: New observations and developments. Essays Biochem 2011,51,137-160","journal-title":"Essays Biochem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31069\/japsr.v2i2.1","volume":"2","author":"Maqbool M.","year":"2019","unstructured":"Maqbool M.; Dar M.A.; Rasool S.; Khan M.; Curious case of drug resistant malaria and artemisinin compounds in the modern era. J Appl Pharm Sci Res 2019,2(2),1-4","journal-title":"J Appl Pharm Sci Res"},{"key":"ref=4","unstructured":"The World Health Organization Guidelines for malaria.  Available from: who.int\/publications\/i\/item\/guidelines-for-malaria"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"Noedl H.","year":"2008","unstructured":"Noedl H.; Se Y.; Schaecher K.; Smith B.L.; Socheat D.; Fukuda M.M.; Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008,359(24),2619-2620","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nrd4573","volume":"14","author":"Wells T.N.C.","year":"2015","unstructured":"Wells T.N.C.; Hooft van Huijsduijnen R.; Van Voorhis W.C.; Malaria medicines: A glass half full? Nat Rev Drug Discov 2015,14(6),424-442","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001169","volume":"9","author":"Delves M.","year":"2012","unstructured":"Delves M.; Plouffe D.; Scheurer C.; Meister S.; Wittlin S.; Winzeler E.A.; Sinden R.E.; Leroy D.; The activities of current antimalarial drugs on the life cycle stages of Plasmodium: A comparative study with human and rodent parasites. PLoS Med 2012,9(2)","journal-title":"PLoS Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2165\/00003495-198529050-00001","volume":"29","author":"Chaffman M.","year":"1985","unstructured":"Chaffman M.; Brogden R.N.; Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs 1985,29(5),387-454","journal-title":"Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.chembiol.2011.09.016","volume":"18","author":"Dong C.K.","year":"2011","unstructured":"Dong C.K.; Urgaonkar S.; Cortese J.F.; Gamo F.J.; Garcia-Bustos J.F.; Lafuente M.J.; Patel V.; Ross L.; Coleman B.I.; Derbyshire E.R.; Clish C.B.; Serrano A.E.; Cromwell M.; Barker R.H.; Dvorin J.D.; Duraisingh M.T.; Wirth D.F.; Clardy J.; Mazitschek R.; Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem Biol 2011,18(12),1602-1610","journal-title":"Chem Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/0006-2952(92)90213-3","volume":"43","author":"Fry M.","year":"1992","unstructured":"Fry M.; Pudney M.; Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4\u2032-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992,43(7),1545-1553","journal-title":"Biochem Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1126\/science.aad9279","volume":"352","author":"Goodman C.D.","year":"2016","unstructured":"Goodman C.D.; Siregar J.E.; Mollard V.; Vega-Rodr&#xED;guez J.; Syafruddin D.; Matsuoka H.; Matsuzaki M.; Toyama T.; Sturm A.; Cozijnsen A.; Jacobs-Lorena M.; Kita K.; Marzuki S.; McFadden G.I.; Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science 2016,352(6283),349-353","journal-title":"Science"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"15746","DOI":"10.1002\/anie.201708454","volume":"56","author":"Fetzer C.","year":"2017","unstructured":"Fetzer C.; Korotkov V.S.; Th&#xE4;nert R.; Lee K.M.; Neuenschwander M.; von Kries J.P.; Medina E.; Sieber S.A.; A chemical disruptor of the CLPX chaperone complex attenuates the virulence of multidrug-resistant Staphylococcus aureus. Angew Chem Int Ed Engl 2017,56(49),15746-15750","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1128\/AAC.02541-14","volume":"58","author":"Boyom F.F.","year":"2014","unstructured":"Boyom F.F.; Fokou P.V.T.; Tchokouaha L.R.Y.; Spangenberg T.; Mfopa A.N.; Kouipou R.M.T.; Mbouna C.J.; Donfack V.F.; Zollo P.H.A.; Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica. Antimicrob Agents Chemother 2014,58(10),5848-5854","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=14","author":"Crane S.","year":"2019","unstructured":"Crane S.; Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof for treating diseases. Can Pat Appl CA Patent 2019","journal-title":"Can Pat Appl CA Patent"},{"key":"ref=15","first-page":"12","volume":"46","author":"Krysin M.Y.","year":"2003","unstructured":"Krysin M.Y.; Petrov V.V.; Shikhaliev K.S.; Gozhina O.V.; Trefilova I.N.; New fused thiazepines, Izvestiya Vysshikh Uchebnykh Zavedenii. Khimiya i Khimicheskaya Tekhnologiya 2003,46,12-14","journal-title":"Khimiya i Khimicheskaya Tekhnologiya"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4236\/ijoc.2020.103009","volume":"10","author":"Gutteridge C.E.","year":"2020","unstructured":"Gutteridge C.E.; Sadowski B.W.; Hughes S.M.; Friedlander J.A.; Rodrigo L.G.; Baxter M.C.; Lorei N.C.; Harrell J.; O\u2019Neil M.T.; Synthesis of substituted benzothiazepine compounds with medicinal potential. Int J Org Chem (Irvine) 2020,10(3),123-134","journal-title":"Int J Org Chem (Irvine)"},{"key":"ref=17","first-page":"466","volume":"4","author":"Cema G.","year":"1968","unstructured":"Cema G.; Rotbergs J.; Oskaja V.; Condensation of dicarboxylic acid anhydrides containing active methylene groups.VII. 5-Chloroind-1,3-dione and its derivatives. Latvijas PSR Zin\u0101tnu akad\u0113mijas v\u0113stis. Kimijas s\u0113rija 1968,4,466-470"},{"key":"ref=18","first-page":"717","volume":"6","author":"Cema G.","year":"1967","unstructured":"Cema G.; Rotbergs J.; Oskaja V.; 5-Methoxyind-1,3-dione. Latvijas PSR Zin\u0101tnu akad\u0113mijas v\u0113stis. Kimijas s\u0113rija 1967,6,717-722"},{"key":"ref=19","first-page":"393","volume":"3","author":"Lusis V.","year":"1984","unstructured":"Lusis V.; Muceniece D.; Zandersons A.; Mazeika I.; Duburs G.; C- and N-alkylation of 4,5-dihydro-1H-indeno[1,2-b]pyridine derivatives. Khimiya Geterotsiklicheskikh Soedinenii 1984,3,393-398","journal-title":"Khimiya Geterotsiklicheskikh Soedinenii"},{"key":"ref=20","first-page":"730","volume":"6","author":"Oskaja V.","year":"1971","unstructured":"Oskaja V.; Synthesis of 4,6-and 5,6-dimethoxyindane-1,3-diones. Latvijas PSR Zin\u0101tnu akad\u0113mijas v\u0113stis. Kimijas s\u0113rija 1971,6,730-734"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1021\/jm000542r","volume":"45","author":"Hodson S.J.","year":"2002","unstructured":"Hodson S.J.; Bishop M.J.; Speake J.D.; Navas F.; Garrison D.T.; Bigham E.C.; Saussy D.L.; Liacos J.A.; Irving P.E.; Gobel M.J.; Sherman B.W.; 2-(Anilinomethyl)imidazolines as &#x3B1;1 adrenergic receptor agonists: the discovery of &#x3B1;1a subtype selective 2\u2032-alkylsulfonyl-substituted analogues. J Med Chem 2002,45(11),2229-2239","journal-title":"J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"Mathis C.A.","year":"2003","unstructured":"Mathis C.A.; Wang Y.; Holt D.P.; Huang G.F.; Debnath M.L.; Klunk W.E.; Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003,46(13),2740-2754","journal-title":"J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ardp.19923251108","volume":"325","author":"L&#xE9;vai A.","year":"1992","unstructured":"L&#xE9;vai A.; Oxazepines and Thiazepines, XXV: Chemical transformations of 2,3-dihydro-1,5-benzothiazepin-4(5H)-ones. Arch Pharm (Weinheim) 1992,325(11),721-726","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1021\/jm200647u","volume":"54","author":"Milner E.","year":"2011","unstructured":"Milner E.; Gardner S.; Moon J.; Grauer K.; Auschwitz J.; Bathurst I.; Caridha D.; Gerena L.; Gettayacamin M.; Johnson J.; Kozar M.; Lee P.; Leed S.; Li Q.; McCalmont W.; Melendez V.; Roncal N.; Sciotti R.; Smith B.; Sousa J.; Tungtaeng A.; Wipf P.; Dow G.; Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum. J Med Chem 2011,54(18),6277-6285","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/AAC.27.4.525","volume":"27","author":"Milhous W.K.","year":"1985","unstructured":"Milhous W.K.; Weatherly N.F.; Bowdre J.H.; Desjardins R.E.; In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother 1985,27(4),525-530","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1128\/AAC.01607-06","volume":"51","author":"Johnson J.D.","year":"2007","unstructured":"Johnson J.D.; Dennull R.A.; Gerena L.; Lopez-Sanchez M.; Roncal N.E.; Waters N.C.; Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother 2007,51(6),1926-1933","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molbiopara.2011.01.002","volume":"177","author":"Hughes L.M.","year":"2011","unstructured":"Hughes L.M.; Lanteri C.A.; O\u2019Neil M.T.; Johnson J.D.; Gribble G.W.; Trumpower B.L.; Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance. Mol Biochem Parasitol 2011,177(1),12-19","journal-title":"Mol Biochem Parasitol"},{"key":"ref=28","first-page":"517","volume":"Vol. 72","author":"Sacci J.B.","year":"2002","unstructured":"Sacci J.B.; Inhibition of liver-stage development assay. In: Doolan, DL, Ed Malaria Methods and Protocols Methods in Molecular Medicine Humana Press2002,Vol. 72,517-520","journal-title":"In: Doolan, DL, Ed Malaria Methods and Protocols Methods in Molecular Medicine"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1128\/AAC.49.3.1169-1176.2005","volume":"49","author":"Jiang S.","year":"2005","unstructured":"Jiang S.; Zeng Q.; Gettayacamin M.; Tungtaeng A.; Wannaying S.; Lim A.; Hansukjariya P.; Okunji C.O.; Zhu S.; Fang D.; Antimalarial activities and therapeutic properties of febrifugine analogs. Antimicrob Agents Chemother 2005,49(3),1169-1176","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0035-9203(90)90066-N","volume":"84","author":"Puri S.K.","year":"1990","unstructured":"Puri S.K.; Dutta G.P.; Quinoline esters as potential antimalarial drugs: Effect on relapses of Plasmodium cynomolgi infections in monkeys. Trans R Soc Trop Med Hyg 1990,84(6),759-760","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187376","volume":"12","author":"Fukuda M.M.","year":"2017","unstructured":"Fukuda M.M.; Krudsood S.; Mohamed K.; Green J.A.; Warrasak S.; Noedl H.; Euswas A.; Ittiverakul M.; Buathong N.; Sriwichai S.; Miller R.S.; Ohrt C.; A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PLoS One 2017,12(11)","journal-title":"PLoS One"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"Lacerda M.V.G.","year":"2019","unstructured":"Lacerda M.V.G.; Llanos-Cuentas A.; Krudsood S.; Lon C.; Saunders D.L.; Mohammed R.; Yilma D.; Batista Pereira D.; Espino F.E.J.; Mia R.Z.; Chuquiyauri R.; Val F.; Casap&#xED;a M.; Monteiro W.M.; Brito M.A.M.; Costa M.R.F.; Buathong N.; Noedl H.; Diro E.; Getie S.; Wubie K.M.; Abdissa A.; Zeynudin A.; Abebe C.; Tada M.S.; Brand F.; Beck H-P.; Angus B.; Duparc S.; Kleim J-P.; Kellam L.M.; Rousell V.M.; Jones S.W.; Hardaker E.; Mohamed K.; Clover D.D.; Fletcher K.; Breton J.J.; Ugwuegbulam C.O.; Green J.A.; Koh G.C.K.W.; Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019,380(3),215-228","journal-title":"N Engl J Med"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220820112324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207786\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220820112324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:54:44Z","timestamp":1692413684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207786\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406418666220820112324","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}